Targets › DUX4
2 programs from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Immunology; next expected readout May 2028.
[Isoform 1]: Transcription factor that is selectively and transiently expressed in cleavage-stage embryos. Binds to double-stranded DNA elements with the consensus sequence 5'-TAATCTAATCA-3'. Binds to chromatin containing histone H3 acetylated at 'Lys-27' (H3K27ac) and promotes deacetylation of H3K27ac. (UniProt, Q9UBX2)
Open in Phaseline: the race on DUX4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Avidity Biosciences | AOC-1020 (Del-brax) Antisense oligonucleotide targeting DUX4 mRNA | DUX4 | Phase 3 | Facioscapulohumeral Muscular Dystrophy | May 2028 |
| Avidity Biosciences | AOC 1020 Antisense oligonucleotide targeting DUX4 mRNA | DUX4 | Phase 2 | FSHD | Apr 2030 |
Facioscapulohumeral Muscular Dystrophy (1) FSHD (1)
small molecule (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.